Back to Authors

Martin, George M.

https://orcid.org/0000-0002-7974-818X

Mayo Clinic

University of Washington

Citations 3

TNF ‐α/ IFN ‐γ synergy amplifies senescence‐associated inflammation and SARS‐CoV ‐2 receptor expression via hyper‐activated
Kandhaya‐Pillai, Renuka , Yang, Xiaomeng , Martin, George M. , Kirkland, James L. , Oshima, Junko , Martin, George M , Oshima, Junko , Tchkonia, Tamar

Aging Cell | May 30, 2022 | Volume: 21 | Issue: 6 | Pages: No page available

10.1111/acel.13646 Get It

Abstract Older age and underlying conditions such as diabetes/obesity or immunosuppression are leading host risk factors for developing severe complications from COVID‐19 infection. The pathogenesis of COVID‐19‐related cytokine storm, tissue damage, and fibrosis may be interconnected with fundamental aging processes, including dysregulated immune responses and cellular senescence. Here, we examined effects of key cytokines linked to cellular senescence on expression of SARS‐CoV‐2 viral entry receptors. We found exposure of human umbilical vein endothelial cells (HUVECs) to the inflammatory cytokines, TNF‐α + IFN‐γ or a cocktail of TNF‐α + IFN‐γ + IL‐6, increased expression of ACE2/DPP4, accentuated the pro‐inflammatory senescence‐associated secretory phenotype (SASP), and decreased cellular proliferative capacity, consistent with progression towards a cellular senescence‐like state. IL‐6 by itself failed to induce substantial effects on viral entry receptors or SASP‐related genes, while synergy between TNF‐α and IFN‐γ initiated a positive feedback loop via hyper‐activation of the JAK/STAT1 pathway, causing SASP amplification. Breaking the interactive loop between senescence and cytokine secretion with JAK inhibitor ruxolitinib or antiviral drug remdesivir prevented hyper‐inflammation, normalized SARS‐CoV‐2 entry receptor expression, and restored HUVECs proliferative capacity. This loop appears to underlie cytokine‐mediated viral entry receptor activation and links with senescence and hyper‐inflammation.
A United States expert consensus to standardise definitions, follow‐up, and treatment targets for extra‐intestinal manifestations in inflammatory bowel disease
Falloon, Katherine , Cohen, Benjamin L., Ananthakrishnan, Ashwin N. , Barnes, Edward L. , Bhattacharya, Abhik , Colombel, Jean‐Frédéric , Driscoll, Marcia S., Ha, Christina , Horst, Sara , Hou, Jason K. , Husni, M. Elaine , Lowder, Careen Y. , Martin, George M. , Sayed, Christopher J. , Schocket, Lisa S. , Siaton, Bernadette C. , Vedak, Priyanka , Rieder, Florian , Colombel, J F. , Horst, Sara , Rieder, Florian , Ananthakrishnan, A N , Sayed, Christopher , Barnes, Edward L , Cross, Raymond K. , Fernandez, Anthony P , Herfarth, Hans , Kroshinsky, Daniela , Kuhn, Kristine A. , Parikh, Deep , Weisman, Michael H.

Alimentary Pharmacology & Therapeutics | March 12, 2022 | Volume: 55 | Issue: 9 | Pages: 1179-1191

10.1111/apt.16853 Get It

SummaryBackground and aimsExtra‐intestinal manifestations (EIMs) are a common complication of inflammatory bowel diseases (IBD), affecting up to half of the patients. Despite their high prevalence, information on standardised definitions, diagnostic strategies, and treatment targets is limited.MethodsAs a starting point for a national EIM study network, an interdisciplinary expert panel of 12 gastroenterologists, 4 rheumatologists, 3 ophthalmologists, 6 dermatologists, and 4 patient representatives was assembled. Modified Delphi consensus methodology was used. Fifty‐four candidate items were derived from the literature review and expert opinion focusing on five major EIMs (erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis) were rated in three voting rounds.ResultsFor use in a clinical practice setting and as part of the creation of a prospective registry of patients with EIMs, the panel developed definitions for erythema nodosum, pyoderma gangrenosum, uveitis, peripheral arthritis, and axial arthritis; identified the appropriate and optimal subspecialists to diagnose and manage each; provided methods to monitor disease course; offered guidance regarding monitoring intervals; and defined resolution and recurrence.ConclusionsConsensus criteria for appropriate and optimal means of diagnosing and monitoring five EIMs have been developed as a starting point to inform clinical practice and future trial design. Key findings include straightforward diagnostic criteria, guidance regarding who can appropriately and optimally diagnose each, and monitoring options that include patient and physician‐reported outcomes. These findings will be used in a national multicenter study network to optimise the management of EIMs.
Evidence‐ and consensus‐based (S3) Guidelines for the Treatment of Actinic Keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version
Werner, Ricardo Niklas , Stockfleth, Eggert , Connolly, S. M., Correia, Osvaldo, Erdmann, R., Gupta, Aditya K. , Jacobs, Anja , Kerl, H., Martin, George M. , Paquet, Maryse, Pariser, David M. , Rosumeck, Stefanie , Röwert‐Huber, Hans‐Joachim, Sahota, A., Sangüeza, Omar P., Sporbeck, Birte, Swanson, Neil A. , Torezan, Luís , Nast, Alexander , Foley, Peter Anthony , Lim, Henry W. , Shumack, Stephen P.

Journal of the European Academy of Dermatology and Venereology | September 15, 2015 | Volume: 29 | Issue: 11 | Pages: 2069-2079

10.1111/jdv.13180 Get It

AbstractBackgroundActinic keratosis (AK) is a frequent health condition attributable to chronic exposure to ultraviolet radiation. Several treatment options are available and evidence based guidelines are missing.ObjectivesThe goal of these evidence‐ and consensus‐based guidelines was the development of treatment recommendations appropriate for different subgroups of patients presenting with AK. A secondary aim of these guidelines was the implementation of knowledge relating to the clinical background of AK, including consensus‐based recommendations for the histopathological definition, diagnosis and the assessment of patients.MethodsThe guidelines development followed a pre‐defined and structured process. For the underlying systematic literature review of interventions for AK, the methodology suggested by the Cochrane Handbook for Systematic Reviews of Interventions, the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was adapted. All recommendations were consented during a consensus conference using a formal consensus methodology. Strength of recommendations was expressed based on the GRADE approach. If expert opinion without external evidence was incorporated into the reasoning for making a certain recommendation, the rationale was provided. The Guidelines underwent open public review and approval by the commissioning societies.ResultsVarious interventions for the treatment of AK have been assessed for their efficacy. The consenting procedure led to a treatment algorithm as shown in the guidelines document. Based on expert consensus, the present guidelines present recommendations on the classification of patients, diagnosis and histopathological definition of AK. Details on the methods and results of the systematic literature review and guideline development process have been published separately.ConclusionsInternational guidelines are intended to be adapted to national or regional circumstances (regulatory approval, availability and reimbursement of treatments).